Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Arcutis Biotherapeutics, Inc. - Common stock (NQ:ARQT)

25.89 -0.82 (-3.07%)
Streaming Delayed Price Updated: 3:50 PM EST, Feb 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Arcutis Biotherapeutics, Inc. - Common stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
Gold Rises Over 1%; Schlumberger Shares Fall After Q3 Results ↗
U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling over 1% on Friday. The Dow traded down 0.31% to 33,309.28 while the NASDAQ fell 1.09% to 13,042.83. The S&P 500 also... 
Via Benzinga
Topics Stocks
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
New Data Shows ZORYVE® (Roflumilast) Cream 0.3% Provided Measurable Improvement of Plaque Psoriasis in Nearly All Individuals in DERMIS Trials
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Analyst Expectations for Arcutis Biotherapeutics's Future ↗
 
Via Benzinga
News headline image
Where Arcutis Biotherapeutics Stands With Analysts ↗
 
Via Benzinga
News headline image
Why Shares of Arcutis Biotherapeutics Fell This Week ↗
The company released phase 3 trial results for an atopic dermatitis cream. 
Via The Motley Fool
News headline image
Why Knight-Swift Transportation Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket ↗
Gainers XORTX Therapeutics Inc. (NASDAQ: XRTX) shares surged 95.5% to $0.6226 in pre-market trading after jumping 34% on Thursday. 
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday ↗
We're closing out the trading week with a breakdown of the biggest pre-market stock movers worth watching on Friday morning! 
Via InvestorPlace
News headline image
Arcutis Announces Pricing of $100 Million Public Offering
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
 
Via Benzinga
News headline image
Arcutis Announces Proposed Public Offering
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For October 13, 2023 ↗
 
Via Benzinga
News headline image
Arcutis Presents Positive Patient-Reported Outcome Data from the Pivotal ARRECTOR Phase 3 Trial in Scalp and Body Psoriasis at European Academy of Dermatology and Venereology (EADV) Congress
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.3% for Treatment of Psoriasis in Children Ages 6 to 11
Expanded indication for ZORYVE provides new, steroid-free topical for children 6 to 11 with plaque psoriasis, including intertriginous psoriasis 
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Arcutis Appoints L. Todd Edwards as Chief Commercial Officer
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Fisker, Intercept Pharmaceuticals, Immunovant And Other Big Stocks Moving Higher On Tuesday ↗
U.S. stocks traded lower, with the Dow Jones falling around 200 points on Tuesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Topics Stocks
News headline image
New Campaign from Arcutis Aims to Educate, Raise Awareness, and Provide Encouragement for Those Living with Seborrheic Dermatitis
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Arcutis Biotherapeutics Reveals Promising Data From Lead Drug In Pediatric Patients With Atopic Dermatitis ↗
Arcutis Biotherapeutics Inc (NASDAQ: ARQT) announced that the INTEGUMENT-PED Phase 3 trial of roflumilast cream 0.05%, in children ages 2 to 5 years with mild to moderate atopic dermatitis met its... 
Via Benzinga
News headline image
Arcutis Announces Positive Results from INTEGUMENT-PED Pivotal Phase 3 Trial of Roflumilast Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Arcutis Submits Roflumilast Cream 0.15% Supplemental New Drug Application to the FDA for the Treatment of Atopic Dermatitis in Adults and Children Ages 6 Years and Older
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
US Stocks Mostly Higher; RH Posts Upbeat Earnings ↗
U.S. stocks traded mostly higher this morning, with the Nasdaq Composite gaining around 60 points on Friday. Following the market opening Friday, the Dow traded down 0.03% to 34,491.98 while the NASDAQ... 
Via Benzinga
Topics Stocks
News headline image
Arcutis Announces Positive Long-Term Results of Roflumilast Cream 0.15% Showing Durable and Improved Efficacy Over Time and Favorable Safety Profile in Treatment of Mild to Moderate Atopic Dermatitis (AD)
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Arcutis to Present at Upcoming Investor Conference
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
3 Biotech Stocks Due for a Massive Short Squeeze ↗
These are the biotech short squeeze candidates to buy and hold for a massive rally of up to 100% in the coming quarters. 
Via InvestorPlace
News headline image
Arcutis Biotherapeutics Publishes Annual Environmental, Social, and Governance (ESG) Report
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Arcutis Launches First Television Ad for ZORYVE® (Roflumilast) Cream 0.3%
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
News headline image
Why Super League Gaming Are Trading Lower By Around 46%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗
Gainers China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) shares jumped 120% to $0.33. 
Via Benzinga
News headline image
Week In Review: Hengrui Out-Licenses Novel Anti-Inflammatory To One Bio In $1 Billion Deal ↗
Jiangsu Hengrui Pharma out-licensed global rights (ex-China) for a novel anti-inflammatory to One Bio of Florida in a $1 billion deal. One Bio will make an $21.5 million payment upfront along with a... 
Via Talk Markets
News headline image
Arcutis Appoints Interim Chief Financial Officer (CFO)
Former and First Arcutis CFO, John Smither, Appointed Interim 
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.